These are references resulting from the pivotal studies for Xolair® (omalizumab) in the treatment of chronic spontaneous urticaria (CSU).
__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
The links below will take you to non-Novartis websites.
Kaplan A et al.
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
J Allergy Clin Immunol 2013;132:101−109.
Maurer M et al.
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
N Engl J Med 2013;368:924−935.
Saini SS et al.
Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
J Invest Dermatol 2015;135:67–75.
*A post hoc analysis of phase 3 studies (ASTERIA I & II, and GLACIAL), demonstrated clinically meaningful improvements in quality of life (measured using DLQI) in patients with CSU.1
CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; IgE, immunoglobulin E.
Reference
- Finlay AY et al. J Eur Acad Dermatol Venereol 2017;31(10):1715–1721.
